A detailed history of American Century Companies Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 143,196 shares of AVIR stock, worth $456,795. This represents 0.0% of its overall portfolio holdings.

Number of Shares
143,196
Previous 125,169 14.4%
Holding current value
$456,795
Previous $414,000 15.7%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.17 - $4.02 $57,145 - $72,468
18,027 Added 14.4%
143,196 $479,000
Q2 2024

Aug 07, 2024

BUY
$3.31 - $4.04 $52,665 - $64,280
15,911 Added 14.56%
125,169 $414,000
Q1 2024

May 14, 2024

BUY
$3.09 - $4.56 $94,257 - $139,098
30,504 Added 38.73%
109,258 $441,000
Q4 2023

Feb 13, 2024

BUY
$2.8 - $3.35 $220,511 - $263,825
78,754 New
78,754 $240,000
Q3 2023

Nov 13, 2023

BUY
$3.0 - $3.79 $64,509 - $81,496
21,503 Added 62.53%
55,893 $167,000
Q2 2023

Aug 14, 2023

BUY
$3.21 - $5.06 $49,292 - $77,701
15,356 Added 80.68%
34,390 $128,000
Q1 2023

May 11, 2023

BUY
$3.0 - $4.97 $5,013 - $8,304
1,671 Added 9.62%
19,034 $63,000
Q4 2022

Feb 13, 2023

BUY
$4.35 - $6.17 $7,638 - $10,834
1,756 Added 11.25%
17,363 $83,000
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $16,266 - $26,044
2,963 Added 23.43%
15,607 $89,000
Q2 2022

Aug 12, 2022

SELL
$5.33 - $8.18 $111,237 - $170,716
-20,870 Reduced 62.27%
12,644 $90,000
Q1 2022

May 11, 2022

SELL
$5.5 - $9.19 $139,771 - $233,545
-25,413 Reduced 43.13%
33,514 $242,000
Q4 2021

Feb 07, 2022

SELL
$7.67 - $44.59 $70,571 - $410,272
-9,201 Reduced 13.51%
58,927 $527,000
Q3 2021

Nov 10, 2021

BUY
$21.33 - $35.06 $1.45 Million - $2.39 Million
68,128 New
68,128 $2.39 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.